On 14 March 2024, Nanologica AB (“Nanologica”), the Swedish life science tools company, announced the successful completion of the rights issue of SEK 54 million. The purpose of the rights issue was to finance intensified efforts and investments in the preparative chromatography business area in order to strengthen the company’s competitiveness and take advantage of the favourable market conditions. The proceeds from the rights issue will primarily be used to enable investments in production equipment to optimize production efficiency and production economics, along with investments in sales, marketing, and application support.
ABG Sundal Collier acted as sole global coordinator and joint bookrunner in the transaction and would like to express its gratitude to the Nanologica team for the vote of confidence.

Contact

Mirjam Medelli

Mirjam Medelli

Investment Banking

mirjam.medelli@abgsc.se +46 8 566 286 61
Laban Blosse

Laban Blosse

Investment Banking

laban.blosse@abgsc.se +46 708 44 86 07
Erik Skog

Erik Skog

Co-Head of ECM and Head of Investment Banking Sweden

erik.skog@abgsc.se +46 8 566 294 71
Oskar Wikberg

Oskar Wikberg

Investment Banking (ECM)

Oskar.Wikberg@abgsc.se +46 8 566 294 79
Ofelia Aspemyr

Ofelia Aspemyr

Investment Banking (ECM)

Ofelia.Aspemyr@abgsc.se +46 8 566 286 31